These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 21220034

  • 1. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
    Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ, Hwang SM, Kim M, Kim HK, Kim I, Yoon SS, Park S, Kim BK, Lee JH, Lee DS, Korea Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
    [Abstract] [Full Text] [Related]

  • 2. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H, Qi X, Jiang A, Xu W, Young T, Reece D.
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA.
    Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
    [Abstract] [Full Text] [Related]

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 5. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
    Jiang N, Qi C, Trieu Y, Reece D, Chang H.
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
    [Abstract] [Full Text] [Related]

  • 6. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D.
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [Abstract] [Full Text] [Related]

  • 7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

  • 8. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan 15; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 9. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.
    Bone Marrow Transplant; 1999 Sep 15; 24(5):497-503. PubMed ID: 10482933
    [Abstract] [Full Text] [Related]

  • 10. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
    Chang H, Qi X, Trieu Y, Xu W, Reader JC, Ning Y, Reece D.
    Br J Haematol; 2006 Nov 15; 135(4):486-91. PubMed ID: 16995883
    [Abstract] [Full Text] [Related]

  • 11. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.
    Haematologica; 2010 Jul 15; 95(7):1150-7. PubMed ID: 20220069
    [Abstract] [Full Text] [Related]

  • 12. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP, Liautard J, Klein B, Brochier J.
    Eur J Immunol; 1997 Dec 15; 27(12):3332-40. PubMed ID: 9464821
    [Abstract] [Full Text] [Related]

  • 13. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR.
    Cancer Res; 2002 Feb 01; 62(3):715-20. PubMed ID: 11830525
    [Abstract] [Full Text] [Related]

  • 14. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 01; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

  • 15. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb 01; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC.
    Clin Cancer Res; 2005 Jun 01; 11(11):4251-8. PubMed ID: 15930364
    [Abstract] [Full Text] [Related]

  • 17. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.
    Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A.
    Cancer; 2000 May 01; 88(9):2061-71. PubMed ID: 10813718
    [Abstract] [Full Text] [Related]

  • 18. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
    Lasfar A, Wietzerbin J, Billard C.
    Eur J Immunol; 1994 Jan 01; 24(1):124-30. PubMed ID: 8020547
    [Abstract] [Full Text] [Related]

  • 19. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan 01; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 20. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.
    J Clin Oncol; 2009 Dec 01; 27(34):5720-6. PubMed ID: 19826130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.